Voloridge Investment Management
TNGX icon

Voloridge Investment Management’s Tango Therapeutics TNGX Stock Holding History

Voloridge Investment Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-255,127
Closed -$2.26M – 1286
2025
Q4 		$2.26M Sell
255,127
-129,080
-34% -$1.11M 0.01% 901
2025
Q3 		$3.23M Buy
+384,207
New +$2.6M 0.01% 839
2024
Q3 		– Sell
-38,201
Closed -$328K – 1363
2024
Q2 		$328K Sell
38,201
-47,960
-56% -$371K ﹤0.01% 1146
2024
Q1 		$684K Sell
86,161
-28,196
-25% -$302K ﹤0.01% 1017
2023
Q4 		$1.13M Buy
+114,357
New +$993K ﹤0.01% 932

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Voloridge Investment Management's TNGX Position: Q1 2026 in Review

Voloridge Investment Management sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 255,127 shares — an estimated $2.26M sold.

Voloridge Investment Management first reported a position in TNGX in Q4 2023 and held it in 5 quarters. The position peaked at $3.23M in Q3 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Voloridge Investment Management reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 255,127 Tango Therapeutics shares in Q1 2026, an estimated $2.26M.
  • Voloridge Investment Management first reported a position in Tango Therapeutics in Q4 2023 and held it in 5 quarters.
  • Voloridge Investment Management's Tango Therapeutics position peaked at $3.23M in Q3 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.